Rentschler Biopharma and Vetter Unveil Xpert Alliance

Article

Rentschler Biopharma and Vetter are unveiling a strategic collaboration called Xpert Alliance.

Rentschler Biopharma and Vetter, two global contract development and manufacturing organizations, are unveiling a joint visualization of their strategic collaboration, Xpert Alliance. The collaboration is focused on delivering effective solutions to address clients’ changing and expanding needs in the biopharmaceutical industry.

Rentschler Biopharma and Vetter entered the alliance in mid-2020, aiming to allow clients to bring their complex products to patients in a faster and easier manner. The companies’ joint visualization Xpert Alliance is focused on the advancement of the alliance and the visibility of the collaborative services the companies offer to clients.

“It is exciting to see how our alliance has been steadily evolving and taking shape,” said Dr. Frank Mathias, CEO of Rentschler Biopharma, in a press release. “We and Vetter have ambitious goals for our collaboration and believe that our clients can greatly benefit from the complementary services and seamless interactions we offer, with the ultimate aim of bringing new, life-changing treatment options to patients.”

“With joint projects ongoing, the day-to-day workings of our strategic alliance are running smoothly, as we work together to create best-in-class solutions for our clients from early development stage through to the market,” added Peter Soelkner, managing director if Vetter, in the release. “We are pleased with the progress we have made so far and look forward to demonstrating the added value we are generating through our collaboration.”
Source: Rentschler Biopharma

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.